Nebenwirkungen · Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)
Lenalidomide Krka d.d. Novo mesto 2.5 mg hard capsules Lenalidomide Krka d.d. Novo mesto 5 mg hard capsules Lenalidomide Krka d.d. Novo mesto 7.5 mg hard capsules Lenalidomide Krka d.d. Novo mesto 10 mg hard capsules Lenalidomide Krka d.d. Novo mesto 15 mg hard capsules Lenalidomide Krka d.d. Novo mesto 20 mg hard capsules Lenalidomide Krka d.d. Novo mesto 25 mg hard capsules · Abschnitt 4.8 · PDF-Seite 21
HOS-148762 · Präparat HOS-099972
Newly diagnosed multiple myeloma: patients who have undergone ASCT treated with lenalidomide maintenance A conservative approach was applied to determine the adverse reactions from CALGB 100104. The adverse reactions described in Table 1 included events reported post-HDM/ASCT as well as events from the maintenance treatment period. A second analysis that identified events that occurred after the start of maintenance treatment suggests that the frequencies described in Table 1 may be higher than actually observed during the maintenance treatment period. In IFM 2005-02, the adverse reactions were from the maintenance treatment period only.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2021-12-17T12:56:00Z · SHA-256 9b15721a878f6b48caf8691524d0cc634862d39053d4ce108521191ff1511e31 · Passage 4c4cb83dc97a82d62878b8f335adce1480a21774acc7dc040edef1fcc4180822 · Zeichen 31–676 im Abschnitt